SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held October 23 to 27, 2019 in Orlando, Florida (“A Novel Spectacle Lens for Myopia Management: From Discovery to Clinical Development” poster session on Sunday, October 27, 2019, Poster 28, Exhibit Hall WE2), according to a company news release.
In addition to the explanation about how a genetic discovery led to the hypothesis that contrast signaling in the retina may play a role in myopia development, the company will present data from the following three key studies:
- PALM was an initial pilot study in children aged 8 to 13 with progressive myopia. One eye was fitted with a SightGlass lens and the fellow eye was fitted with a control single vision lens. The SightGlass lens was well tolerated and resulted in significantly less progression, as measured by axial length change, compared to the control eye;
- WALNUT demonstrated tolerability of three optimized spectacle lens designs. Of note, all three lens designs showed a trend toward reduction in axial length over the two weeks of lens wear, with one design reaching statistical significance in both eyes (P<0.05); and,
- CYPRESS is an ongoing, multicenter, double-masked, randomized controlled pivotal clinical study in children aged 6 to 10 years old and having myopia between -0.75 D and -4.5 D (spherical equivalent refraction) at the time of enrollment. Data from this trial will be used to support registration and market launch of the Company’s novel lenses. The 12-month results from CYPRESS will be available in Q2 2020.
“We are excited to share for the first time with the medical community the story of our novel spectacle lenses designed to manage myopia in children–from concept to the clinic. We look forward to reporting the planned, 1-year results from our pivotal trial, CYPRESS, in Q2 2020, followed by additional data with longer-term follow up,” Joe Rappon, OD, MS, FAAO, Chief Medical Officer, said in the news release.